Animal vs Human Peptide Research
For many peptides on this site the evidence is animal data. This page explains why an animal result does not show the same outcome in people.
Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.
Animal and human results can disagree
A 2007 systematic review compared animal experiments with clinical trials for six interventions whose effect in people was clear. Corticosteroids showed a benefit in animal models of head injury (pooled odds ratio for adverse functional outcome 0.58) but no benefit in clinical trials; tirilazad reduced infarct volume by 29% in animal models of stroke but was associated with a worse outcome in patients. The authors conclude that discordance “may be due to bias or to the failure of animal models to mimic clinical disease adequately” (Perel 2007, PMID 17175568). Other interventions in the same review showed effects in both: thrombolysis improved outcome in stroke patients and tissue plasminogen activator reduced infarct volume by 24% in animal models, and bisphosphonates raised bone mineral density in patients and alendronate did so in animal models.
Dose extrapolation is not a per-kilogram multiplication
FDA’s guidance on starting doses for first-in-human trials works from an animal no observed adverse effect level, a body-surface-area conversion and a safety factor, not from a dose that worked in an animal. See allometric scaling failures.
Species differences
FDA’s guidance notes that some biologic therapies have “very limited interspecies cross-reactivity or pronounced immunogenicity”, which limits what animal safety data can show. A 2026 comparison of human and mouse nodose ganglia found differences in where the GLP-1 receptor gene is expressed (Merchant 2026, PMID 41618954). Both are discussed on the allometric scaling page.
Publication bias
In a review of 16 systematic reviews of animal stroke studies (525 publications), only ten publications (2%) reported no significant effect on infarct volume, and the authors estimate that publication bias might account for around one-third of the efficacy reported (Sena 2010, PMID 20361022). That is one field; it shows how the published record of an animal literature can look stronger than the studies actually run.
What this means in practice
On PeptideStacks, claims supported only by animal evidence receive a Grade C (or lower) by default. A compound with a strong preclinical record but no human trial data is not, on our methodology, considered established for any human use. See: evidence grading methodology.
If you spot an error or have new evidence to suggest, please use our corrections policy.